Physician profile
James E Veselka
NPI 1609850841
$1,866.43
in general payments reported to CMS, 2019-2025
18 companies · $19.82 in 2025
The $19.82 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $556 · 2020: $476 · 2021: $681 · 2022: $15.33 · 2023: $105 · 2024: $13.45 · 2025: $19.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $138.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $519.86 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.61 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $170.90 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $102.02 | 2019-2021 | |
| Abbvie INC. | $79.04 | 2021 | |
| Merck Sharp & Dohme LLC | $75.65 | 2019-2021 | |
| Allergan, INC. | $69.99 | 2020 | |
| Lilly USA, LLC | $67.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $58.92 | 2021-2023 | Shingrix, Arexvy, Bexsero |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.25 | 2019-2021 | |
| Esperion Therapeutics, INC. | $56.53 | 2021 | |
| Exact Sciences Corporation | $46.83 | 2023-2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $43.91 | 2021-2023 | Rybelsus, Ozempic |
| Eisai INC. | $42.25 | 2020-2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.60 | 2021 | |
| Abbott Laboratories | $40.07 | 2022-2023 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Veselka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.